Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:227831918" >
17β-Estradiol suppr...
17β-Estradiol suppresses visceral adipogenesis and activates brown adipose tissue-specific gene expression
-
- Al-Qahtani, SM (författare)
- Karolinska Institutet
-
- Bryzgalova, G (författare)
- Karolinska Institutet
-
- Valladolid-Acebes, I (författare)
- Karolinska Institutet
-
visa fler...
-
- Korach-André, M (författare)
- Karolinska Institutet
-
Dahlman-Wright, K (författare)
-
Efendić, S (författare)
-
Berggren, PO (författare)
-
Portwood, N (författare)
-
visa färre...
-
(creator_code:org_t)
- Walter de Gruyter GmbH, 2017
- 2017
- Engelska.
-
Ingår i: Hormone molecular biology and clinical investigation. - : Walter de Gruyter GmbH. - 1868-1891 .- 1868-1883. ; 29:1, s. 13-26
- Relaterad länk:
-
http://kipublication...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Both functional ovaries and estrogen replacement therapy (ERT) reduce the risk of type 2 diabetes (T2D). Understanding the mechanisms underlying the antidiabetic effects of 17β-estradiol (E2) may permit the development of a molecular targeting strategy for the treatment of metabolic disease. This study examines how the promotion of insulin sensitivity and weight loss by E2 treatment in high-fat-diet (HFD)-fed mice involve several anti-adipogenic processes in the visceral adipose tissue. Magnetic resonance imaging (MRI) revealed specific reductions in visceral adipose tissue volume in HFD+E2 mice, compared with HFD mice. This loss of adiposity was associated with diminished visceral adipocyte size and reductions in expression of lipogenic genes, adipokines and of the nuclear receptor
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas